Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 53.00
-0.82 (-1.52%)
At close: Feb 6, 2026
SHA:688192 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 607.75 | 359.9 | 91.29 | - | 10.29 | - |
Other Revenue | - | - | - | - | - | 27.76 |
| 607.75 | 359.9 | 91.29 | - | 10.29 | 27.76 | |
Revenue Growth (YoY) | 55.98% | 294.25% | - | - | -62.95% | -32.32% |
Cost of Revenue | 29.47 | 11.84 | 7.66 | 3.65 | 12.93 | 26.56 |
Gross Profit | 578.28 | 348.06 | 83.63 | -3.65 | -2.65 | 1.2 |
Selling, General & Admin | 699.87 | 598.78 | 437.55 | 128.44 | 87.95 | 340.43 |
Research & Development | 797.67 | 721.16 | 801.15 | 660.87 | 583.67 | 423.94 |
Other Operating Expenses | -17.56 | -2.1 | -0.27 | -0.39 | 0.1 | 0.49 |
Operating Expenses | 1,481 | 1,318 | 1,239 | 788.9 | 671.73 | 764.84 |
Operating Income | -902.31 | -969.66 | -1,155 | -792.55 | -674.37 | -763.65 |
Interest Expense | -30.9 | -22.75 | -7.57 | -4.34 | -3.07 | - |
Interest & Investment Income | 2.45 | 2.24 | 3.64 | 2.53 | 3.65 | 3.89 |
Currency Exchange Gain (Loss) | -2.45 | -2.45 | -1.45 | 10.1 | -6.45 | -28.9 |
Other Non Operating Income (Expenses) | -0.36 | -0.07 | -0.04 | -0.03 | -0.08 | -0.33 |
EBT Excluding Unusual Items | -933.58 | -992.69 | -1,161 | -784.3 | -680.32 | -788.99 |
Gain (Loss) on Sale of Investments | 22.08 | 14.45 | 22.52 | 42.16 | 0.97 | 0.29 |
Gain (Loss) on Sale of Assets | 0 | - | -0.01 | 0.02 | - | 198.82 |
Other Unusual Items | 38.59 | 38.59 | 30.5 | 6.39 | 9.47 | 3.29 |
Pretax Income | -872.91 | -939.65 | -1,108 | -735.74 | -669.88 | -586.58 |
Income Tax Expense | 0.05 | 0 | 0.1 | 0.26 | - | 0.03 |
Earnings From Continuing Operations | -872.96 | -939.66 | -1,108 | -736 | -669.88 | -586.61 |
Minority Interest in Earnings | 5.52 | 93.7 | - | - | - | - |
Net Income | -867.44 | -845.96 | -1,108 | -736 | -669.88 | -586.61 |
Net Income to Common | -867.44 | -845.96 | -1,108 | -736 | -669.88 | -586.61 |
Shares Outstanding (Basic) | 434 | 415 | 407 | 404 | 360 | 360 |
Shares Outstanding (Diluted) | 434 | 415 | 407 | 404 | 360 | 360 |
Shares Change (YoY) | 5.52% | 1.83% | 0.70% | 12.29% | 0.07% | - |
EPS (Basic) | -2.00 | -2.04 | -2.72 | -1.82 | -1.86 | -1.63 |
EPS (Diluted) | -2.00 | -2.04 | -2.72 | -1.82 | -1.86 | -1.63 |
Free Cash Flow | -804.72 | -788.1 | -1,000 | -677.15 | -501.26 | -621.75 |
Free Cash Flow Per Share | -1.85 | -1.90 | -2.46 | -1.67 | -1.39 | -1.73 |
Gross Margin | 95.15% | 96.71% | 91.61% | - | -25.72% | 4.31% |
Operating Margin | -148.47% | -269.43% | -1265.43% | - | -6556.55% | -2750.82% |
Profit Margin | -142.73% | -235.05% | -1213.42% | - | -6512.85% | -2113.09% |
Free Cash Flow Margin | -132.41% | -218.98% | -1095.44% | - | -4873.51% | -2239.65% |
EBITDA | -863.75 | -930.08 | -1,114 | -753.85 | -636.97 | -733.83 |
EBITDA Margin | -142.12% | -258.43% | - | - | - | - |
D&A For EBITDA | 38.56 | 39.58 | 40.94 | 38.7 | 37.4 | 29.82 |
EBIT | -902.31 | -969.66 | -1,155 | -792.55 | -674.37 | -763.65 |
EBIT Margin | -148.47% | -269.43% | - | - | - | - |
Revenue as Reported | 607.75 | 359.9 | 91.29 | - | 10.29 | 27.76 |
Advertising Expenses | - | - | - | 1.94 | - | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.